Omnicell

Traded on the St. Petersburg Stock Exchange
Omnicell, Inc. is an American multinational healthcare technology company. It manufactures automated systems for medication management in hospitals and other healthcare settings, and medication adherence packaging and patient engagement software used by retail pharmacies. Its products are sold under the brand names Omnicell and EnlivenHealth.
Omnicell stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Omnicell balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Omnicell cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Omnicell multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Omnicell profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Omnicell assets
Omnicell cash flows

Omnicell shares

TickerNameTypeNominal valueISINPrice
OMCL:USOmnicell, Inc.Common share-US68213N1090$27.93
Omnicell news
29.04.2022
Net income of Omnicell under GAAP for the 3 months of 2022 was $8.213 million, down 41.9% from $14.127 million in the previous year. Revenues increased 26.6% to $318.828 million from $251.843 million a year earlier.
15.02.2022
Omnicell's GAAP net income for 2021 was $77.849 million, up 2.4 times from $32.194 million in the previous year. Revenue increased 26.9% to $1.132 billion from $0.892 billion a year earlier.
02.11.2021
Omnicell's GAAP net income for 9M 2021 amounted to $63.868 million, a fourfold increase from $15.817 million in the previous year. Revenues increased 27.7% to $820.984 million from $643.006 million a year earlier.
29.07.2021
Omnicell's GAAP net income for 6 months of 2021 amounted to $34.551 million, up 4.9 times from $7.012 million in the previous year. Revenues increased 22.2% to $524.582 million from $429.307 million a year earlier.
General information
Company nameOmnicell
SectorInformation Technology / Software & Services / Software / Application Software
Business address590 E. MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 6502516100
Mailing address590 E. MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Websitewww.omnicell.com
Information disclosurewww.sec.gov